It also showed that the EGFR/LOX pathway may play a role in the anti-metastasis effects of silibinin in NSCLC, which provides a scientific basis for developing silibinin into an anti-cancer drug. This evidence concerns the gene EGFR and non-small cell lung carcinoma.